• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

FIGO score ≥13 associated with early gestational trophoblastic disease death

byDenise PongandLeah Hawkins Bressler, MD, MPH
October 4, 2015
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with an International Federation of Gynecology and Obstetrics (FIGO) score ≥13 comprised three-quarters of early deaths.

2. Among high-risk patients, mortality was significantly higher among women with FIGO score ≥13.

Evidence Rating Level: 2 (Good)           

Study Rundown: Gestational trophoblastic neoplasia (GTN) is a group of malignancies that includes invasive mole, gestational choriocarcinoma and 2 rare tumor types. GTN can be preceded by hydatiform moles or nonmolar pregnancies. Risk factors for GTN include prior molar pregnancy and advanced maternal age. Presenting symptoms may vary depending on the type of malignancy but include vaginal bleeding, uterine enlargement, pelvic pain, anemia, hyperemesis gravidarum, hyperthyroidism and early preeclampsia. Treatment is dictated by FIGO prognosis scoring and consists of single agent or combination chemotherapy. Prognosis can be evaluated using the FIGO prognosis scoring system, which accounts for age, type of antecedent pregnancy (partial mole, complete mole, spontaneous abortion, vaginal delivery), time since pregnancy, β-hCG level, tumor size, number and location of metastases and history of failed chemotherapy. Prior evidence shows that FIGO score ≥7 is associated with poorer prognosis. In the present study, authors explored factors associated with the highest risk of early death and found that women with FIGO score ≥13 were most likely to experience death within 4 weeks of treatment and had higher mortality at 5 years.

Strengths of the study included large population database and long-term follow-up. Limitations included selection bias, retrospective design, and variability in chemotherapy regimens, which may be a confounding factor in the observed results. Further prospective studies and randomized controlled trials are needed to identify a threshold for which combination therapy may be preferable for treatment of GTN.

Click to read the study in AJOG

RELATED REPORTS

The quadrivalent human papillomavirus vaccine provides effective and durable protection against invasive cervical cancer

2 Minute Medicine Rewind March 2, 2026

Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia

Relevant Reading: The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment

In-Depth [retrospective cohort]: This study evaluated the clinical characteristics and outcomes of 974 women with GTN. The primary outcomes of interest were survival and early death, defined as death within 4 weeks of treatment initiation.

Among the 140 patients classified as high-risk (FIGO score ≥7), the 5-year mortality rate was 38.4% for women with FIGO score ≥13, compared with 4.9% in women with FIGO score <13 (p < 0.0001). 75% of early deaths were among women with FIGO score ≥13.

Image: CC/Wiki/Nephron

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: gestational trophoblastic disease (GTD)gynecologic oncology
Previous Post

Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants

Next Post

Intrapartum antibiotics associated with altered infant gut microbiome

RelatedReports

Quick Take: T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
Chronic Disease

The quadrivalent human papillomavirus vaccine provides effective and durable protection against invasive cervical cancer

March 6, 2026
Few older adolescents meet recommended levels of physical activity
Weekly Rewinds

2 Minute Medicine Rewind March 2, 2026

March 2, 2026
American-born Asian women more likely to have endometrial cancer
Endocrinology

Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia

February 16, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Chronic Disease

Early menarche and later menopause are associated with increased ovarian cancer risk

February 13, 2026
Next Post
Intrapartum antibiotics associated with altered infant gut microbiome

Intrapartum antibiotics associated with altered infant gut microbiome

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The WOEST trial: Double vs. triple therapy in patients requiring PCI and anticoagulation [Classics Series]

Adolescent views on marijuana and alcohol associated with future DUI

Adolescent views on marijuana and alcohol associated with future DUI

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Food coloring additives are associated with higher incidence of type 2 diabetes
  • Children conceived through infertility treatments may have similar growth compared to naturally conceived children
  • Ring-augmented one-anastomosis gastric bypass may not improve weight loss compared to conventional one-anastomosis gastric bypass
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.